8 completed, 2 recruiting, 1 not yet recruiting. 9 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 6, Recruiting 2, Not yet recruiting 1 |
| Phase 3 | 1 | Completed 1 |
Follow TASK Applied Science: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Combinations of Novel Promising Drugs for Pulmonary Tuberculosis TBAJ-587 50 mg, Pretomanid 200mg, Linezolid 600Mg Tab - Tuberculosis, Pulmonary | Phase 2 | Not yet recruiting | TASK Applied Science | 135 | 2026-09-25 | 2026-09-25 |
| A Study of the Early Effects, Safety, and Acceptability of Oral Alpibectir in Combination With Ethionamide Alpibectir 45 mg once daily (OD) plus Ethionamide 125 mg OD, Alpibectir 45 mg OD plus Ethionamide 250 mg OD, Isoniazid, rifampicin, pyrazinamide and ethambutol fixed dose combination, weight based - Tuberculosis | Phase 2 | Recruiting | TASK Applied Science | 60 | 2025-03-03 | 2025-03-07 |
| Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB Ganfeborole, BTZ-043, Bedaquiline (B) - Pulmonary Tuberculosis | Phase 2 | Recruiting | University College, London | 2500 | 2024-01-09 | 2026-10-15 |
| A Phase 2 Trial to Evaluate the EBA, Safety and Tolerability of Eto Alone and in Combination With BVL-GSK098 BVL-GSK098 9mg, Ethionamide 250mg, Ethionamide 250 mg - Rifampicin- and Isoniazid-Susceptible Pulmonary Tuberculosis (TB) | Phase 2 | Completed | TASK Applied Science | 105 | 2022-12-06 | 2025-08-21 |
| Pharmacokinetics of Ethionamide and Ethionamide Sulfoxide in Patients Established on Treatment for Tuberculosis. Plasma samples - Tuberculosis, Pulmonary | Completed | BioVersys AG | 30 | 2022-06-10 | 2023-11-21 | |
| EBA, Safety and Tolerability of Sanfetrinem Cilexetil Sanfetrinem Cilexetil, Rifampicin - Tuberculosis, Pulmonary | Phase 2 | Completed | TASK Applied Science | 54 | 2022-04-21 | 2025-02-21 |
| Evaluating the EBA of Meropenem With Amoxicillin/Clavulanate and Pyrazinamide or Bedaquiline in Adults With PTB Meropenem Injection, Amoxicillin Clavulanate, Pyrazinamide - Tuberculosis | Phase 2 | Completed | TASK Applied Science | 22 | 2020-08-17 | 2022-01-25 |
| BCG Vaccination for Healthcare Workers in COVID-19 Pandemic Bacille Calmette-Guérin (BCG), Placebo Comparator - COVID-19, Sars-CoV2 | Phase 3 | Completed | TASK Applied Science | 1000 | 2020-05-04 | 2022-01-25 |
| Study to Evaluate H56:IC31 in Preventing Rate of TB Recurrence H56:IC31, Placebo - Tuberculosis, Pulmonary | Phase 2 | Completed | International AIDS Vaccine Initiative | 831 | 2019-01-31 | 2026-02-24 |
| Study to Evaluate EBA, Safety and Tolerability of Carbapenems in Adults With Pulmonary Tuberculosis Meropenem 6g IV over 6 hours, Ertapenem 1g IM, Meropenem 3g IV - Pulmonary Tuberculosis | Phase 2 | Completed | TASK Applied Science | 134 | 2017-11-09 | 2023-06-09 |
| Phase 2 Trial to Evaluate the Early Bactericidal Activity, Safety and Tolerability of Meropenem Plus Amoxycillin/CA and Faropenem Plus Amoxycillin/CA in Adult Patients With Newly Diagnosed Pulmonary Tuberculosis Meropenem, Faropenem, Amoxycillin/clavulanic acid - Pulmonary Tuberculosis | Phase 2 | Completed | TASK Applied Science | 46 | 2014-09-01 | 2018-09-13 |
Tuberculosis, Pulmonary (8) · Tuberculosis (4) · COVID-19 (1) · Recurrence (1) · Reinfection (1)
Rifampin (5) · Isoniazid (4) · Pyrazinamide (4) · Meropenem (3) · 2-(2-methyl-1,4-dioxa-8-azaspiro(4.5)dec-8-yl)-8-nitro-6-(trifluoromethyl)-4H-1,3-benzothiazin-4-one (2) · Amoxicillin-Potassium Clavulanate Combination (2) · Ethambutol (2) · Ethionamide (2) · Linezolid (2) · bedaquiline (2) · pretomanid (2) · Ertapenem (1) · Fumigant 93 (1) · GSK656 (1) · Moxifloxacin (1)
South Africa (11) · Tanzania (2) · Moldova (1) · Uganda (1) · Vietnam (1)
Fairoez Ryklief, MBBChB (1) · Gifty Okyere-Manu, MBChB (1) · Glenn Dale (1) · Marissa Russell (1) · Prof Andreas H Diacon, MD, PhD (1) · Reinard McPherson, MBChB (1) · Veronique R De Jager, MBChB (1)
PMID 35582122, PMID 37401774, PMID 39803560, PMID 40020440, PMID 40056922, PMID 42482138